Anti-Mouse CTLA-4 (CD152) Monoclonal Antibodies

Background of Anti-Mouse CTLA-4 (CD152) Antibody

The UC10-4F10-11 antibody blocks the mouse cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells.

PA007545.m2a: In Vivo Grade Recombinant Anti-mouse CTLA-4 (CD152) Monoclonal Antibody (Clone: UC10-4F10-11), Mouse IgG2a Kappa

Recombinant mouse IgG2a Monoclonal Antibody.
Clone: UC10-4F10-11.
Isotype: Mouse IgG2a kappa.
Source: The anti-mouse CTLA-4 (CD152) monoclonal antibody (clone: UC10-4F10-11) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: UC10-4F10-11) specifically binds to mouse CTLA-4 (CD152).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CTLA-4 (CD152) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

PA007545.hs: In Vivo Grade Recombinant Anti-mouse CTLA-4 (CD152) Monoclonal Antibody (Clone: UC10-4F10-11), Armenian hamster IgG

Recombinant hamster IgG Monoclonal Antibody.
Clone: UC10-4F10-11.
Isotype: Armenian hamster IgG.
Source: The anti-mouse CTLA-4 (CD152) monoclonal antibody (clone: UC10-4F10-11) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: UC10-4F10-11) specifically binds to mouse CTLA-4 (CD152).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CTLA-4 (CD152) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The in vivo grade recombinant anti-mouse CTLA-4 (CD152) monoclonal antibody of clone UC10-4F10-11 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

Syd Labs provides the following recombinant anti-mouse CTLA-4 antibodies:
In vivo grade recombinant anti-mouse CTLA-4 monoclonal antibodies (clone 9D9)

Syd Labs provides the following research grade anti-CTLA-4 antibody biosimilars:
Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Recombinant CTLA-4 Proteins:
Biotinylated Human CTLA-4 Protein
Cynomolgus CTLA-4 Protein
Human CTLA-4 Protein

References of Anti-mouse CTLA-4 (CD152) Monoclonal Antibody:

Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
Makkouk, A. et al. Cancer Immunol Res. 2015 Apr;3(4):389-98. doi: 10.1158/2326-6066.CIR-14-0173. PMID: 25627654
(iii) sustaining T-cell responses by checkpoint blockade using anti?CTLA-4. ...We chose to focus on anti-OX40 due to its demonstrated synergistic activity with anti?CTLA-4, which enhances antitumor immune responses in murine lymphoma models. ...The activity of T cells is tightly regulated by checkpoints that control the magnitude of the immune response, exemplified by cytotoxic T-lymphocyte antigen 4 (CTLA-4). ...On the basis of this background, we hypothesized that a three-step approach to in situ immunization (doxorubicin microparticles given intratumorally combined with systemic anti?CTLA-4 and anti-OX40) can elicit a systemic curative adaptive immune response. ...A stimulatory antibody that activates OX40 (anti-OX40) could thus be used to further activate tumor-specific T cells.
Tags: anti-mouse CTLA-4 (CD152) UC10-4F10-11; anti-mouse CTLA-4 (CD152) UC10-4F10-11 mAb

The viral context instructs the redundancy of costimulatory pathways in driving CD8(+) T cell expansion.
Welten, S. P. M. et al. eLife. 2015 Aug 11;4:e07486. doi: 10.7554/eLife.07486. PMID: 26263500
Next, we examined if additional triggering of the CD28/B7 costimulatory pathway is able to differentially modulate effector T cell formation. Therefore, the co-inhibitory receptor CTLA-4 that binds to B7.1 and B7.2 was blocked with antibodies during infection, which increases the availability of the B7 molecules to stimulate CD28. ...Remarkably, CTLA-4 blockade during LCMV infection had no effect on T cell expansion, indicating that LCMV-specific CD8+ T cells are rather indifferent to enhanced B7-mediated signals. ...However, CTLA-4 blockade during MCMV infection augmented MCMV-specific CD8+ T cell responses ?threefold in a B7-dependent manner. ...Thus, additional triggering of the CD28/B7 pathway is beneficial in settings in which T cell expansion is dependent on this pathway, while the enhancement of CD28/B7-mediated costimulation had no effect in conditions in which the B7 costimulatory molecules are not essential for initial T cell expansion. ...Of interest is that even further improvement of B7-mediated signaling due to CTLA-4 blockade did not advance LCMV-specific CD8+ T cell expansion, suggesting that the observed higher expression of costimulatory molecules is at a maximal level with respect to stimulating T cells.
Tags: anti-mouse CTLA-4 (CD152) UC10-4F10-11 in vivo; anti-mouse CTLA-4 (CD152) UC10-4F10-11 in animal model

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.
Zhu, Y. et al. Cancer Res. 2014 Sep 15;74(18):5057-69. doi: 10.1158/0008-5472.CAN-13-3723. PMID: 25082815
Investigations of this response revealed that CSF1R blockade also upregulated T-cell checkpoint molecules, including PDL1 and CTLA4, thereby restraining beneficial therapeutic effects. ...We found that PD1 and CTLA4 antagonists showed limited efficacy as single agents to restrain PDAC growth, but that combining these with CSF1R blockade potently elicited tumor regressions, even in larger established tumors. ...However, in response to reduced immune suppression, programmed death 1 ligand 1 (PDL1) is upregulated on tumor cells and cytotoxic T lymphocyte antigen 4 (CTLA4) on T cells. ...In contrast, CTLA4 expression on CD8+ CTLs was significantly upregulated by CSF1R inhibition. ...These checkpoints will likely limit the efficacy of observed antitumor immune responses.
Tags: anti-mouse CTLA-4 (CD152) UC10-4F10-11 mAb in animal model; function of anti-mouse CTLA-4 (CD152) UC10-4F10-11

Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard, B. et al. Clin Cancer Res. 2013 Oct 15;19(20):5626-35. doi: 10.1158/1078-0432.CCR-13-0545. PMID: 23983257
Monoclonal antibodies (mAb) that block programmed death (PD)-1 or cytotoxic T lymphocyte antigen (CTLA-4) receptors have been associated with durable clinical responses against a variety of cancer types and hold great potential as novel cancer therapeutics. ...In this study, we investigated whether targeted blockade of CD73, an ectonucleotidase that catabolizes the hydrolysis of extracellular adenosine monophosphate (AMP) to adenosine, can enhance the antitumor activity of anti-CTLA-4 and anti-PD-1 mAbs against transplanted and chemically induced mouse tumors. ...Anti-CD73 mAb significantly enhanced the activity of both anti-CTLA-4 and anti-PD-1 mAbs against MC38-OVA (colon) and RM-1 (prostate) subcutaneous tumors, and established metastatic 4T1.2 breast cancer. ...We investigated the effect of extracellular adenosine on tumor-infiltrating T cells and showed that activation of A2A adenosine receptor enhances PD-1 expression, but not CTLA-4 expression, on tumor-specific CD8+ T cells and CD4+ Foxp3+ T regulatory cells. ...The first immune-checkpoint inhibitor approved for cancer treatment is the anti-CTLA-4 mAb ipilimumab.
Tags: anti-mouse CTLA-4 (CD152) UC10-4F10-11; anti-CTLA-4 (CD152) clone UC10-4F10-11

The CTLA-4 and PD-1/PD-L1 inhibitory pathways independently regulate host resistance to Plasmodium-induced acute immune pathology.
Hafalla, J. C. R. et al. PLoS Pathog. 2012 Feb;8(2):e1002504. doi: 10.1371/journal.ppat.1002504. PMID: 22319445
Two important T cell inhibitory pathways involve signalling through members of the CD28:B7 superfamily of costimulatory molecules, namely cytotoxic T lymphocyte antigen-4 (CTLA-4; CD152) and programmed death-1 (PD-1; CD279). ...While CTLA-4 is expressed on activated T cells including regulatory T cells, PD-1 is broadly expressed on activated T cells, regulatory T cells and other haematopoietic cells. ...T cell activation through the T cell receptor (TCR) and the costimulatory molecule CD28 results in increased expression of CTLA-4. ...Since both CD28 and CTLA-4 bind to B7-1 (CD80) and B7-2 (CD86) on antigen-presenting cells, sequential expression of CD28 and then CTLA-4 allows T cells to be intrinsically self-regulating. ...CTLA-4 has higher affinity to the B7 molecules than CD28.
Tags: bioactivity of anti-mouse CTLA-4 (CD152) UC10-4F10-11; bioactivity of anti-mouse CTLA-4 (CD152) UC10-4F10-11 mAb

CD4+ natural regulatory T cells prevent experimental cerebral malaria via CTLA-4 when expanded in vivo.
Haque, A. et al. PLoS Pathog. 2010 Dec;6(12):e1001221. doi: 10.1371/journal.ppat.1001221. PMID: 21170302
The molecular mechanisms by which Treg cells perform these functions are incompletely understood, but have been reported to involve production of cytokines such as TGF? and IL-10, and increased expression of the negative regulatory molecule CTLA-4. ...Furthermore, Foxp3+ cell-mediated protection was dependent upon CTLA-4 but not IL-10. ...Since IL-2Jc treatment increased IL-10 and CTLA-4 expression by Foxp3+ CD4+ T cells during infection, we hypothesized that protection was dependent upon these two molecules. ...We further analysed the effects of IL-2Jc on Treg cells, and observed that their expression of CD25, Foxp3 and CTLA-4 was substantially elevated by IL-2Jc treatment compared to control saline treated, infected mice. ...Taken together, these data demonstrate that IL-2Jc treatment triggers the expansion of natural CD4+ Treg cells, which then express higher levels of Foxp3, IL-10 and CTLA-4 in response to PbA infection.
Tags: anti-mouse CTLA-4 (CD152) UC10-4F10-11 antibody in cancer research; anti-mouse CTLA-4 (CD152) UC10-4F10-11 in mouse tumor model

For more references about Anti-mouse CTLA-4 (CD152) Monoclonal Antibody please contact our scientific support team with message@sydlabs.com.